Pharmacoeconomic Evaluation of Lipid Nanoparticle-Based Drug Delivery Systems in Chronic Disease Management: A Cost-Effectiveness Analysis

Abstract

The increasing prevalence of chronic diseases such as diabetes mellitus, cardiovascular disorders, rheumatoid arthritis, and cancer has intensified the demand for innovative therapeutic interventions that improve clinical outcomes while maintaining economic sustainability. Lipid nanoparticle (LNP)-based drug delivery systems have emerged as a promising nanotechnology platform capable of enhancing drug bioavailability, targeted delivery, and therapeutic efficacy. However, the economic implications of adopting these advanced formulations remain inadequately explored. The present study evaluates the cost-effectiveness of lipid nanoparticle formulations in chronic disease management from a healthcare management and pharmacoeconomic perspective. Secondary data were collected from published studies, healthcare reports, and pharmacoeconomic literature. Comparative analysis was conducted between conventional drug delivery systems and LNP-based formulations using cost-effectiveness indicators, treatment adherence measures, hospitalization reduction rates, and quality-adjusted life years (QALYs). Findings indicate that although LNP formulations involve higher initial treatment costs, they contribute to reduced hospitalization expenses, improved patient compliance, enhanced therapeutic outcomes, and better long-term economic value. The study highlights the significance of integrating pharmacoeconomic assessments into healthcare decision-making and supports the adoption of nanotechnology-driven therapies within sustainable healthcare management frameworks.